S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDYFritz Offner, Jeffrey Matous, Lingling Chen et al.|HemaSphere|2023Cited by 31
P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDYCarlyn Tan, Cyrille Touzeau, Emma Searle et al.|HemaSphere|2023Cited by 7
CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Joanna Rhodes et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)Krina K. Patel, Matthew Ku, Joanna Rhodes et al.|Hematological Oncology|2025Cited by 0
ORAL ABSTRACT: CT-1498 A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (Car) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)Krish Patel, Matthew Ku, Joanna Rhodes et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0